{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:24:35Z","timestamp":1765959875183,"version":"3.41.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jbspin.2016.10.011","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T15:31:19Z","timestamp":1483111879000},"page":"571-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study"],"prefix":"10.1016","volume":"84","author":[{"given":"Xavier","family":"Mariette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieke","family":"Alten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert G.","family":"N\u00fc\u00dflein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Cantagrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Le Bars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2016.10.011_bib0150","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","article-title":"Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion","volume":"46","author":"Moreland","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0155","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/rheumatology\/keq287","article-title":"Abatacept treatment for rheumatoid arthritis","volume":"50","author":"Schiff","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0160","unstructured":"Orencia (250mg powder for concentrate for solution for infusion) Summary of Product Characteristics. Available from URL: http:\/\/www.medicines.org.uk\/emc\/medicine\/19714\/SPC\/ [Accessed 10 Sep 2015]."},{"key":"10.1016\/j.jbspin.2016.10.011_bib0165","unstructured":"Product monograph: Orencia (abatacept). Available from URL: http:\/\/www.bmscanada.ca\/static\/products\/en\/pm_pdf\/ORENCIA_EN_PM.pdf [Accessed 10 Sep 2015]."},{"key":"10.1016\/j.jbspin.2016.10.011_bib0170","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/rheumatology\/keq266","article-title":"Obesity in rheumatoid arthritis","volume":"50","author":"Stavropoulos-Kalinoglou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0175","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0180","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.22185","article-title":"Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis","volume":"66","author":"Labitigan","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0185","first-page":"1989","article-title":"Obesity and the risk for development of rheumatoid arthritis\u00a0\u2013\u00a0results from a population-based nested case-control study","volume":"67","author":"Ljung","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0190","first-page":"59","article-title":"Impact of obesity on the disease course of rheumatoid arthritis","volume":"67","author":"Liu","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0195","first-page":"1926","article-title":"The clinical impact of overweight in rheumatoid arthritis patients: comparison between Korea and other countries within the Comora study","volume":"67","author":"Shin","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0205","first-page":"478","article-title":"Body mass index and response to infliximab in rheumatoid arthritis","volume":"33","author":"Ottaviani","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0210","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/annrheumdis-2013-205094","article-title":"Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis","volume":"73","author":"Sandberg","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jbspin.2014.12.006","article-title":"Obesity reduces the drug survival of second line biological drugs following a first TNF-alpha inhibitor in rheumatoid arthritis patients","volume":"82","author":"Iannone","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2015-eular.1727","article-title":"In patients with rheumatoid arthritis and an inadequate response to methotrexate, does body mass index influence the efficacy of abatacept on inflammation when measured by power doppler ultrasonography? Results from the APPRAISE study","volume":"74","author":"D\u2019Agostino","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0225","first-page":"489","article-title":"Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study","volume":"34","author":"N\u00fc\u00dflein","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0230","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/annrheumdis-2014-eular.5630","article-title":"Body mass does not affect clinical outcomes of therapy with abatacept in rheumatoid arthritis (RA) patients. A pan-European analysis of RA registries","volume":"73","author":"Iannone","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0235","first-page":"460","article-title":"Pharmacokinetics of subcutaneous abatacept support a fixed dosing regimen in adult patients with rheumatoid arthritis","volume":"70","author":"Murthy","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0240","first-page":"1088","article-title":"Does body mass index impact long-term retention with abatacept in patients with RA who have received at least one prior biologic agent? 2-year results from a real-world, international, prospective study","volume":"66","author":"N\u00fc\u00dflein","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2474-15-14","article-title":"Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study","volume":"15","author":"N\u00fc\u00dflein","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0260","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0265","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3899\/jrheum.140673","article-title":"Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient","volume":"42","author":"Pers","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0270","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10067-016-3183-3","article-title":"Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study","volume":"35","author":"Gardette","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0275","first-page":"S574","article-title":"Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity","volume":"68","author":"Corbo","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0280","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.it.2003.10.013","article-title":"Inflammation: the link between insulin resistance, obesity and diabetes","volume":"25","author":"Dandona","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0285","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar3900","article-title":"Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis","volume":"14","author":"Stavropoulos-Kalinoglou","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2016.10.011_bib0290","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1097\/MD.0000000000000888","article-title":"Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study","volume":"94","author":"Ursini","year":"2015","journal-title":"Medicine (Baltimore)"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X1630210X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X1630210X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T23:34:47Z","timestamp":1749857687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X1630210X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1297319X1630210X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.011","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}